CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Gelteq Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Gelteq Ltd
Level 4, 100 Albert Road
Phone: +61 390873990p:+61 390873990 MELBOURNE, VIC  3205  Australia Ticker: GELSGELS
Business Summary
Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a highly versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20226/30/2021YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Simon H.Szewach 44 8/5/2021 8/5/2021
Chief Executive Officer, Executive Director Nathan J.Givoni 40
Chief Financial Officer Anthony W.Panther 61 2/5/2024 2/5/2024
3 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 9,560,303 (As of 8/30/2022)
Stock Exchange: NASD


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, November 19, 2024